2019 European Dermatological Congress: La Roche-Posay Presents Its Latest Research On Allergies, Atopic Dermatitis & Acne

News provided by

Oct 10, 2019, 12:08 ET

NEW YORK, Oct. 10, 2019 /PRNewswire/ -- For the 24^th year in a row, La Roche-Posay will be present at the European Academy of Dermatology and Venerology (EADV) Congress that will take place in Madrid from October 9 to October 13 2019. The brand will showcase findings from its most recent clinical studies on major skin issues. Research includes an exclusive epidemiological study on allergy prevalence and management conducted with over 11000 people, a study on pain and atopic dermatitis and an assessment of the efficacy and tolerance of sunscreen in acne-prone people.

NEW FINDINGS ON ALLERGY
Performed in five countries (Brazil, China, France, Russia and the United States) on 11,069 adults, the exclusive allergy epidemiology study conducted in 2019 by La Roche-Posay found that a significant part of the adult population declare to have allergies (from 20.2% in France up to 41.7% in the United States ). Between 65% and 82% of these people had their diagnosis confirmed by healthcare professionals.¹

Additionally, the study demonstrates that skin reactions are a very common consequence of allergies, irrespective of type (food, respiratory or skin). A majority of participants in each country, from 53% in France to 75% in Russia and 89% in China, reported a manifestation on their skin associated with allergic episodes. These reactions vary from pruritus to tightness, tickling, numbness, burning and pain. To manage these reactions, 58% of patients in France and up to 79% of those in China visit a doctor who in most cases prescribes a topical or oral treatment. The management of skin reactions caused by allergies with dermocosmetics remains low, between 14% and 26% in the five countries.¹

"We know that more and more people suffer from allergies across the globe," said Sophie Seite, Scientific Director, La Roche-Posay. "In fact, according to the European Academy and Clinical Immunology, 50% of all Europeans will suffer from an allergy by 2025. What our research has shown is that all types of allergies have an impact on the skin. Reactions on the skin are an important concern for allergic people, and well-formulated, effective dermocosmetics can offer a real benefit to them."

53% of those suffering from any type of allergies in France experience a skin reaction during allergic episodes. It's 89% in China.

ATOPIC DERMATITIS & PAIN
In addition to the allergy epidemiological study, La Roche-Posay will also share results from research focused on atopic dermatitis. While pruritus in atopic dermatitis has been extensively studied in the past, information about the pain associated with the skin condition is very limited. A recent online survey conducted by the brand among 5,000 people showed that almost 55% of those suffering from atopic dermatitis experience pain. Patients with painful atopic dermatitis were also more likely to consult a dermatologist (68.3% vs. 36.9% of those without skin pain) or a general practitioner (98% vs. 92.9%).²

55% of those suffering from atopic dermatitis experience pain.

SUN EXPOSURE & ACNE
Another important piece of research shared by La Roche-Posay at EADV Congress focuses on highlighting the importance of sunscreen in the management of acne. It is known that while sun exposure may improve acne appearance on the short-term, it does aggravate overall outcomes. In a single-centre, open-use study involving young adults with acne-prone skin, a sunscreen combining high UV protection and active ingredients was tested to determine its anti-imperfection and mattifying effects. From the first month of sunscreen application, people experienced an improvement of their skin condition that was maintained after 4 months of application, with fewer imperfections and marks. In addition, there was a significant reduction in the greasy aspect of their skin.³

80% of those with acne-prone skin found that they had less imperfections and marks after using a sunscreen with efficient UV protection and active ingredients against spots.

WHEN SKIN ISSUES IMPACT PRODUCTIVITY
Two other posters from La Roche-Posay emphasize the impact on quality of life of skin conditions, with a focus on productivity loss. The first study highlights the reduction of absenteeism at work caused by acne-prone skin when using an optimal skincare routine. The second poster presents the findings of a study on people with eye allergies which reveals that more than half of them consider they are less efficient at work during allergic episodes and 6% of them reported sick leaves due to their allergies.⁴

La Roche-Posay will cover the event live on its Instagram channel (@larocheposay) with exclusive interviews of experts and key information from the onsite presentations.

KEY FIGURES

15 posters in total presented by La Roche-Posay at 2019 European dermatological Congress
24 years. La Roche-Posay has been present at the EADV since 1995
+90 posters presented since 1995 on skin care topics such as the microbiome, allergies, etc.
11 000 people participated in the exclusive 2019 allergy survey conducted by the brand

About La Roche-Posay:
Recommended by 90,000 dermatologists worldwide⁵, La Roche-Posay's mission is to offer a better life for sensitive skin. Created by a pharmacist in 1975, the brand is now present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their patients' treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin. For additional information about La Roche-Posay, visit www.laroche-posay.com and follow La Roche-Posay on Facebook, Instagram and Twitter.

^{^[1]} Posters P0928, P0929, P0165, P0173, P0174 presented at the 2019 European Academy of Dermatology and Venerology (EADV ) Congress

^[2]Poster P0244 presented at the 2019 European Academy of Dermatology and Venerology (EADV ) Congress

^[3]Poster P0244 presented at the 2019 European Academy of Dermatology and Venerology (EADV ) Congress

^[4]Posters P0025 presented at the 2019 European Academy of Dermatology and Venerology (EADV ) Congress

^[5]Source: Survey on the dermocosmetic market carried out by IQVIA and other partners (Ipsos, TNS) between September 2017 and August 2018 among dermatologists in 62 countries

SOURCE La Roche-Posay